L3VLUP
ProSign in

UTHR · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

UTHRVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • UTHR
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterUTHRVRTX
Q3 202010 holders, $797m31 holders, $21.9bn
Q4 202011 holders, $1.2bn30 holders, $18.4bn
Q1 202110 holders, $1.4bn31 holders, $15.4bn
Q2 202111 holders, $1.5bn30 holders, $12.7bn
Q3 202116 holders, $1.5bn35 holders, $10.1bn
Q4 202114 holders, $1.9bn28 holders, $12.4bn
Q1 202214 holders, $1.7bn23 holders, $16.1bn
Q2 202218 holders, $2.3bn25 holders, $18.1bn
Q3 202217 holders, $2.2bn22 holders, $18.4bn
Q4 202218 holders, $2.9bn28 holders, $18.4bn
Q1 202316 holders, $2.5bn26 holders, $21.4bn
Q2 202312 holders, $2.5bn27 holders, $24.7bn
Q3 202313 holders, $2.4bn33 holders, $24.3bn
Q4 202314 holders, $2.3bn32 holders, $28.6bn
Q1 202419 holders, $2.2bn31 holders, $29.8bn
Q2 202414 holders, $2.5bn29 holders, $33.4bn
Q3 202410 holders, $2.9bn27 holders, $33.5bn
Q4 202414 holders, $3.3bn26 holders, $28.5bn
Q1 202514 holders, $2.1bn21 holders, $35.4bn
Q2 202514 holders, $1.9bn21 holders, $32.3bn
Q3 202516 holders, $2.6bn22 holders, $25.9bn
Q4 202514 holders, $3.8bn26 holders, $31.8bn
Q1 202618 holders, $5.1bn25 holders, $31.8bn
Q2 202614 holders, $3.5bn26 holders, $34.6bn
UTHR

United Therapeutics Corp Del

Holders
18
Reported value
$5.1bn
Buyers
18
Sellers
17

Breadth +1 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
25
Reported value
$31.8bn
Buyers
17
Sellers
21

Breadth -4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 31 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only UTHR (6)

AQR Capital Management LLC, Citadel Advisors LLC, Freestone Grove Partners LP, Millennium Management LLC, Point72 Asset Management LP, Winton Group Ltd

Only VRTX (13)

Arrowstreet Capital LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., ExodusPoint Capital Management LP, Fidelity (FMR LLC), Holocene Advisors LP, MFS Investment Management, Neuberger Berman Group LLC, Two Sigma Investments LP, Walleye Capital LLC, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →